|

Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

RECRUITINGPhase 2/3Sponsored by Ain Shams University
Actively Recruiting
PhasePhase 2/3
SponsorAin Shams University
Started2025-04-01
Est. completion2026-05-01
Eligibility
Age15 Years – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06951074

Summary

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

Eligibility

Age: 15 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Type 1 diabetes

Exclusion Criteria:

* patients with other autoimmune diseases
* patients with micro or macro vascular complications
* patients with other chronic diseases

Conditions3

DiabetesStem CellsType 1 Diabetes

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.